To appraise the clinical and cost effectiveness of letermovir within its marketing authorisation for preventing cytomegalovirus reactivation or disease in people with sero-positive-CMV who have had an allogeneic haematopoietic stem cell transplant.
 
 
Status In progress
Process STA pre-2018
ID number 1153

Provisional Schedule

Appraisal consultation: 1 04 July 2018 - 25 July 2018
Expected publication 14 November 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck, Sharp & Dohme (letermovir)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Anthony Nolan
Professional groups Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  The British Society for Haematology

Commentators

Comparator companies Actavis (CAU not returned, not participating)
  Accord Healthcare (CAU not returned, not participating)
  Aurobindo (CAU not returned, not participating)
  Clinigen (CAU not returned, not participating)
  GlaxoSmithKline (aciclovir, valaciclovir)
  Hospira (CAU not returned, not participating)
  Roche Products (CAU not returned, not participating)
  Rosemont (CAU not returned, not participating)
  Sun pharmaceutical (acyclovir, valacicilovir) (CAU not returned, not participating)
  Thame Labratories (CAU not returned, not participating)
  Thorton & Ross (CAU not returned, not participating)
  Wockhardt (CAU not returned, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
12 June 2018 Committee meeting: 1
09 January 2018 Invitation to participate
14 July 2017 - 11 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
09 January 0008 In progress, Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance